Tradestie Institutional Equity Comparison Engine
CYBN vs BHST โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CYBN Overall Edge
CYBN Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cybin Inc. (CYBN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CYBN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, CYBN sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CYBN N/M vs BHST N/M Fwd P/E
Growth & Margin Winner
CYBN
Op Margin 0.0% vs -18.0% ยท YoY +0.0% vs +3.8%
Momentum & Technical Winner
CYBN
1Y -8.0% vs -79.4% ยท 52W Pos 59% vs 6%
Options & Structure Winner
CYBN
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
CYBN
NYSE American
Cybin Inc.
Pharmaceutical Preparations
$8.28
+1.22% 1D
Market Cap
$413.4M
1M Return
+50.27%
1Y Return
-8.0%
Forward P/E
N/M
Unified AI Score
63.8 / 100
BUY
Tech 75.0
Fund 66.0
Flow 58.0
Mom 70.0
BHST
NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap
$29.9M
1M Return
-22.62%
1Y Return
-79.4%
Forward P/E
N/M
Unified AI Score
58.2 / 100
HOLD
Tech 75.0
Fund 57.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CYBN -8.0%
BHST -79.4%
Spread: +57.06 pp (CYBN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CYBN TTM Op. Margin: 0.0%
BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CYBN vs BHST. Trailing 12-month operating profitability (CYBN 0.0% vs BHST -18.0%) and valuation multiples (CYBN N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CYBN | BHST | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $413.4M | $29.9M | Larger Scale | CYBN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +3.8% | Higher Growth | BHST |
| Operating Margin (TTM) Profitability | 0.0% | -18.0% | Higher Margin | CYBN |
| Net Profit Margin Profitability | 0.0% | -31.2% | Higher Margin | CYBN |
| Return on Equity (ROE) Capital Efficiency | -53.0% | -142.5% | Higher ROE | CYBN |
| 52-Week Range Position Momentum | 59% ($5โ$11) | 6% ($1โ$7) | Stronger Trend | CYBN |
| Beta / 30D Volatility Risk Regime | 1.50ฮฒ ยท 54% Vol | 0.25ฮฒ ยท 86% Vol | Lower Realized Risk | CYBN |
| Unified Institutional Score Composite Signal | 63.8 / 100 (BUY) | 58.2 / 100 (HOLD) | Higher Composite | CYBN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CYBN vs BHST Buy Guide
CYBN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
BHST
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CYBN nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.